louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02980159: Impact of a Triage Liaison Physician
Official title: Impact of a Triage Liaison Physician on the Time to First Medical Evaluation in the Emergency Departement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Emergencies
Triage
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2016-12-02
Enrollment: 69893
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patient admitted in GUH ED during 2 years.

Brief summary: Due to an increasing number of patients admitted in emergency departments, many patients cannot be evaluated immediately after their admission. The function of "triage liaison physician" was introduced in Spring 2015. The objective of this study is to evaluate the impact of this new function on patients' flow in the ED.

Detailed description: Geneva University Hospitals (GUH) emergency department (ED) admits more than 64000 patients every year. These patients are triaged using the Swiss Emergency Triage Scale (SETS), a 4-level triage scale. The SETS imposes time objectives until the first medical evaluation (20 minutes for SETS 2, 2 hours for SETS 3). In 2014, only 60% of level-2 and 63% of level-3 emergencies were evaluated within 20 and 120 minutes respectively.

A triage liaison physician was introduced in Spring 2015 with the mission to help triage nurse in their decisions and to evaluate quickly the patients that cannot be immediately installed in an ED evaluation room.

The objective of this study is to evaluate the impact of the triage liaison physician on the times to first medical evaluation.

Eligibility criteria: Inclusion Criteria:

* \>= 16 y
* admitted in GUH ED

Exclusion Criteria:

* patients triaged to outpatient clinics

Primary outcomes:
measure: Proportion of patients evaluated within SETS objectives
timeFrame: Within 120 minutes after ED triage
Secondary outcomes:
measure: Time to first medical contact
timeFrame: Within 24 hours after ED triage
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University Hospitals, ED
Study officials:
affiliation: University Hospital, Geneva
name: Olivier T Rutschmann, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03260959: Experience of the Father Following the Announcement of a First Pregnancy
Official title: Experience of the Father Following the Announcement of a First Pregnancy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Family Relations
Behavior
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-08-24
Enrollment: 45
Sex: MALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)

Brief summary: Experience of the father following the announcement of a first pregnancy Its context, immediate reactions and actions. Possible impact of this moment of life a few months or years later?


Eligibility criteria: Inclusion Criteria:

- Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)

Exclusion Criteria:

* Patients with severe or neurological psychiatric disorders inducing significant cognitive impairment
* Patients who do not master the French language
* Patients who cannot give free and informed consent (guardianship, curatorship, safeguard of justice ...)

Primary outcomes:
measure: Interview by hierarchical evocation's method
timeFrame: 30-45 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Beynost
country: France
facility: Cabinet de médecine générale
city: Crémieu
country: France
facility: Cabinet de médecine générale
city: Lyon
country: France
facility: Cabinet de médecine générale
city: Vallon-Pont-d'Arc
country: France
facility: Cabinet de médecine générale
city: Vaugneray
country: France
facility: Cabinet de médecine générale
Study officials:
References:
Clinical trial NCT04472559: Acupressure for COVID-19 Related Quality of Life and Stress
Official title: Randomized Controlled Trial of Acupressure for Health-Related Quality of Life and Perception of Stress Among Health Care Providers During the COVID-19 Pandemic
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Quality of Life
Stress
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2020-07-15
Enrollment: 164
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is being conducted to evaluate the efficacy of acupressure in promoting health and well-being among healthcare workers during the COVID-19 pandemic. The investigators hypothesize that providing participants with a remote and standardized self-acupressure training program will improve HRQOL and the perception of stress. In the event that the study demonstrates acupressure to be safe and effective for this indication, the training could be scaled up and deployed at low-cost nationally and internationally.


Eligibility criteria: Inclusion Criteria:

* All adult patients (18 years of age and over) who are health care providers according to self-report will be eligible for participation with the exception of subjects meeting exclusion criteria as below.

Exclusion Criteria:

* Exclusion criteria includes subjects who are physically unable to participate (e.g., from severe arthritis) or cognitively unable to participate (e.g., from dementia) will be excluded. Patients unable to provide their own informed consent will be excluded. Patients under the age of 18 years will be excluded. Pregnant women will be excluded. Patients who have previous training in acupressure will be excluded.

Primary outcomes:
measure: Health Related Quality of Life
timeFrame: 8 weeks
measure: Perception of stress
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Ka-Kit Hui, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01723059: Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection
Official title: Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Helicobacter Infection
Lead sponsor: Dallas VA Medical Center
Sponsor class: FED
Collaborators: name: Otsuka Pharmaceutical Development & Commercialization, Inc.
First posted: 2012-11-07
Enrollment: 184
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Traditionally, H pylori infection has been treated with conventional triple therapy. This includes amoxicillin, clarithromycin and a proton pump inhibitor all given daily for 10-14 days. In Europe, the guidelines now advocate treatment of H pylori with sequential therapy which is 5 days of amoxicillin therapy with proton pump inhibitor followed by 5 days of clarithromycin, metronidazole, and proton pump inhibitor with better response rates. We hypothesize that H. pylori resistance pattern and treatment response rates observed in Europe will not be predictive of resistance patterns and response rates in the United States.


Eligibility criteria: Inclusion Criteria:

Subject has signed informed consent Subject is an adult older than 18 yrs old and requires an upper endoscopic evaluation If female and of child bearing potential, subject has a negative pregnancy test and is not nursing.

Patient has not received prior treatment for H pylori Subject is able to understand and comply with study procedures

Exclusion Criteria:

Recent use (within 4 weeks) of any of the medications used in the treatment of H pylori(Amoxicillin, Clarithromycin, Metronidazole) Subject undergoing endoscopy for acute gastrointestinal bleeding Subject has an allergy to any of the medications used in the treatment of H pylori Subject has a history of esophageal or gastric carcinoma including lymphoma Subject has esophageal varices or undergoing endoscopy for esophageal banding Subject is taking warfarin or clopidogrel Subject has coagulopathy that precludes safe biopsy of the biopsy areas Subject has comorbidity that precludes safe participation in the study Subject is a pregnant female Subject has a history of H. pylori infection. Patient is already enrolled in GI Study. History of UGI surgery other than Nissen Fundoplication

Primary outcomes:
measure: Helicobacter pylori eradication
timeFrame: 4 weeks after completion of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Dallas VAMC
state: Texas
Study officials:
affiliation: Gastroenterologist, MD VA
name: Byron Cryer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Pathologist, MD
name: Robert Genta, MD
role: STUDY_CHAIR
affiliation: Gastroenterology Fellow, MD
name: Elizabeth Coss, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02016859: Observational Prospective Study of the Predicted Value of Immature Thrombocytes Counts in Three Different Groups of Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critically Ill Patients
Neutropenic Fever Patients
Patients With Hip Fractures
Keywords: IPF Immature platelet fraction
ICU neutropenic fever
hip fracture
critically ill
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2013-12-20
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: admmitted patients to multiple departements

Brief summary: Immature Platelet Fraction (IPF) is a new value in CBC blood tests Recent Studies showed that this value may be another prognostic factor in critically ill patients such as those admitted to ICU, or those with neutropenic Fever.

The purpose of the study is to check if the IPF may be used as a prognostic Factor in these patients

Detailed description: In this study we have 3 groups of patients

* Patients admitted to ICU
* Patients admitted with neutropenic fever
* Patients admitted with hip fractures it is a prospective study, not interventional, we'll take blood samples of these patients including CBC count eith IPF and other inflammation markers such as CRP and we'll compare CRP to IPF in addition to clinical follow-up of the patient till discharge.

At the end of this study we'll compare the efficacy of IPF as a prognostic Factor in these patients

Eligibility criteria: Inclusion Criteria:

- Admission to hospital blood sample is taken between 24:00 pm till 15:00 pm

Exclusion Criteria:

* blood sample is taken after 15:00 pm in the first day of admission during the week
* blood sample is taken on weekend: thursday 15:00 pm till saturday 24:00 pm

Primary outcomes:
measure: Time to recovery from sepsis or time to death
timeFrame: 6 months
Secondary outcomes:
measure: Predicting value of IPF for prognosis
timeFrame: baeline 6 months
Other outcomes:
measure: clinical use of IPF as a prognostic factor
timeFrame: up to 12 months
Locations:
city: Haifa
country: Israel
facility: Rambam Health care campus
Study officials:
References:
citation: Di Mario A, Garzia M, Leone F, Arcangeli A, Pagano L, Zini G. Immature platelet fraction (IPF) in hospitalized patients with neutrophilia and suspected bacterial infection. J Infect. 2009 Sep;59(3):201-6. doi: 10.1016/j.jinf.2009.07.007. Epub 2009 Jul 18.
citation: De Blasi RA, Cardelli P, Costante A, Sandri M, Mercieri M, Arcioni R. Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med. 2013 Apr;39(4):636-43. doi: 10.1007/s00134-012-2725-7. Epub 2012 Oct 24.
Clinical trial NCT02864459: The Role of Muscular Ultrasound in Predicting Weaning Success
Official title: The Role of Muscular Ultrasound in Predicting Weaning Success
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiratory Insufficiency
Keywords: Ultrasonography
Weaning
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-08-12
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: When attempting to wean a patient from the ventilator, even if he/she passes the spontaneous breathing test, 10-20% of the time extubation failure occurs and the patient is reintubated. When the patient is reintubated the mortality rate increases and the length of intensive care unit stay is also increased. It is vital to intensively assess the patient before extubation and correctly predict extubation success. Muscular ultrasound may be helpful in these situations.


Eligibility criteria: Inclusion Criteria:

* Adult patients undergoing weaning from mechanical ventilation
* Patients who have been mechanically ventilated for more than 72 hrs

Exclusion Criteria:

* Pregnant patients
* Patients with previous neuromuscular diseases
* Difficulties in muscular ultrasound (Dressing, operation, etc)

Primary outcomes:
measure: Extubation success (no need for reintubation)
timeFrame: 48 hours after extubation
Secondary outcomes:
measure: Weaning success (no need for applying the ventilator again)
timeFrame: 2 hours after spontaneous breathing trial
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University
Study officials:
References:
Clinical trial NCT01625559: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)
Official title: A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Stargardt's Macular Dystrophy
Lead sponsor: CHABiotech CO., Ltd
Sponsor class: INDUSTRY
First posted: 2012-06-21
Enrollment: 3
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD

Detailed description: * to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD
* to evaluate the preliminary efficacy of MA09-hPRE in patients with SMD

Eligibility criteria: Inclusion Criteria:

* Adult male or female over 20 years of age.
* Clinical diagnosis of advanced SMD.
* The visual acuity of the eye to receive the transplant will be no better than hand movement.
* The visual acuity of the eye that is not to receive the transplant will be no better than 24 (20/320) Early Treatment of Diabetic Retinopathy Study (ETDRS) letters.

Exclusion Criteria:

* History of malignancy.
* History of myocardial infarction in previous 12 months.
* History of diabetes mellitus.
* Any immunodeficiency.
* Any current immunosuppressive therapy other than intermittent or low dose cortico steroids.
* Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.
* Current participation in any other clinical trial.
* Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.
* Any other sight-threatening ocular disease.
* Any chronic ocular medications. Any history of retinal vascular disease (compromised blood-retinal barrier). Glaucoma. Uveitis or other intraocular inflammatory disease. Significant lens opacities or other media opacity. Ocular lens removal within previous 3 months

Primary outcomes:
measure: safety and tolerance of transplantation
timeFrame: 18 months
Secondary outcomes:
measure: Evidence of successful engraftment
timeFrame: 18 months
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: CHA Bundang Medical Center
state: Gyeonggi-do
Study officials:
affiliation: CHA Bundang Medical Center
name: Wonkyung Song
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sung Y, Lee MJ, Choi J, Jung SY, Chong SY, Sung JH, Shim SH, Song WK. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br J Ophthalmol. 2021 Jun;105(6):829-837. doi: 10.1136/bjophthalmol-2020-316225. Epub 2020 Jul 29.
Clinical trial NCT02883959: Evaluation of the Analgesic Effect of Music Therapy in Critically Ill Patients During Potentially Painful Nursing Procedures: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: critically ill
mechanical ventilation
pain
nursing
music
Lead sponsor: Versailles Hospital
Sponsor class: OTHER
First posted: 2016-08-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pain is a common problem encountered in about 60 % of critically ill patients who can communicate. Its occurrence can be related to several causes, mainly dominated by invasive procedures.

Pain management is typically based on a combination of prevention, evaluation, and therapeutic agents. However, it appears important to develop adjuvant approaches. Music therapy is one of them and that has been evaluated in various medical conditions.

The aim of our study is to evaluate the analgesic effect of music therapy in critically ill patients during potentially painful nursing procedures.


Eligibility criteria: Inclusion Criteria:

* All adult patients (age≥18 years) hospitalized in Intensive Care Unit
* Requiring mechanical ventilation
* Who cannot communicate
* With a Richmond Agitation Sedation Scale (RASS) score \[-3; +4\]

Exclusion Criteria:

* Age \< 18 years
* Receiving neuromuscular blockade

Primary outcomes:
measure: proportion of pain exposure during nursing procedures
timeFrame: 150 minutes
Secondary outcomes:
measure: proportion of maximal pain exposure during nursing procedures
timeFrame: 150 minutes
Other outcomes:
Locations:
city: Le Chesnay
country: France
facility: CH Versailles
Study officials:
References:
citation: Jacq G, Melot K, Bezou M, Foucault L, Courau-Courtois J, Cavelot S, Lang A, Bedos JP, Le-Boeuf D, Boussard JM, Legriel S. Music for pain relief during bed bathing of mechanically ventilated patients: A pilot study. PLoS One. 2018 Nov 14;13(11):e0207174. doi: 10.1371/journal.pone.0207174. eCollection 2018.
Clinical trial NCT05379959: Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
Official title: Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Stimulant Use
MDMA ('Ecstasy')
Social Behavior
Motivation
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2022-05-18
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To study the effects of MDMA, compared to a prototypical stimulant, on social motivation, social ability, and neural indices of social function in healthy volunteers


Eligibility criteria: Inclusion Criteria:

* BMI between 19 and 30 (no one under 130 lbs)
* Smokers smoking less than 25 cigarettes per week
* Have used ecstasy no more than 40 times with no adverse responses.

Exclusion Criteria:

* High blood pressure
* Any medical condition requiring regular medication
* Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
* Individuals with a history of dependence on stimulant drugs.
* Women who are pregnant or trying to become pregnant

Primary outcomes:
measure: Profile of Mood States
timeFrame: Time Frame: Baseline-72 hours after completion of the sessions
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
References:
Clinical trial NCT01860859: Suture of UTerus and Ultrasound Repair Evaluation
Official title: Randomized Controlled Trial Comparing Three Techniques of Uterine Closure on the Myometrium Thickness Evaluated With Ultrasound Six Months After a Primary Cesarean
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uterine Scar Defect
Keywords: cesarean
ultrasound
hysterotomy
uterus
suture
Lead sponsor: CHU de Quebec-Universite Laval
Sponsor class: OTHER
Collaborators: name: Laval University
name: Université de Montréal
First posted: 2013-05-23
Enrollment: 81
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study compares three techniques of uterine closure on myometrium thickness evaluated by ultrasound six months after the primary cesarean. The three techniques include: 1) locked single layer closure; 2) double layer closure with a first continuous locked suture and a second imbricating continuous suture; 3) double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium. The primary outcome is the mean myometrium thickness at the site of the uterine scar evaluated by transvaginal ultrasound at six months after cesarean.


Eligibility criteria: Inclusion Criteria:

* Planned cesarean
* Primary cesarean
* ≥ 38 gestational weeks

Exclusion Criteria:

* Previous cesarean
* Women \< 18 years old
* Multiple gestation
* Mullerian anomalies
* Active labor
* Diabetes
* BMI \>35 kg/m2
* Placenta praevia
* Chronic systemic disease

Primary outcomes:
measure: Mean myometrium thickness
timeFrame: 6 months after intervention
Secondary outcomes:
measure: Estimated blood loss
timeFrame: Same day of intervention: day 1
measure: Operative time
timeFrame: Same day of intervention: day 1
measure: Mean number of haemostatic sutures
timeFrame: Same day of intervention: day 1
Other outcomes:
Locations:
city: Québec
country: Canada
facility: CHU de Québec
state: Quebec
Study officials:
References:
citation: Roberge S, Boutin A, Chaillet N, Moore L, Jastrow N, Demers S, Bujold E. Systematic review of cesarean scar assessment in the nonpregnant state: imaging techniques and uterine scar defect. Am J Perinatol. 2012 Jun;29(6):465-71. doi: 10.1055/s-0032-1304829. Epub 2012 Mar 7.
citation: Roberge S, Chaillet N, Boutin A, Moore L, Jastrow N, Brassard N, Gauthier RJ, Hudic I, Shipp TD, Weimar CH, Fatusic Z, Demers S, Bujold E. Single- versus double-layer closure of the hysterotomy incision during cesarean delivery and risk of uterine rupture. Int J Gynaecol Obstet. 2011 Oct;115(1):5-10. doi: 10.1016/j.ijgo.2011.04.013. Epub 2011 Jul 26.